Logo image of ALEC

ALECTOR INC (ALEC) Stock Fundamental Analysis

NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD

1.61  -0.02 (-1.23%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALEC. ALEC was compared to 559 industry peers in the Biotechnology industry. ALEC may be in some trouble as it scores bad on both profitability and health. ALEC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALEC has reported negative net income.
ALEC had a negative operating cash flow in the past year.
In the past 5 years ALEC always reported negative net income.
In the past 5 years ALEC reported 4 times negative operating cash flow.
ALEC Yearly Net Income VS EBIT VS OCF VS FCFALEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

ALEC's Return On Assets of -30.23% is fine compared to the rest of the industry. ALEC outperforms 66.37% of its industry peers.
ALEC's Return On Equity of -130.47% is in line compared to the rest of the industry. ALEC outperforms 40.25% of its industry peers.
Industry RankSector Rank
ROA -30.23%
ROE -130.47%
ROIC N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ALEC Yearly ROA, ROE, ROICALEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEC Yearly Profit, Operating, Gross MarginsALEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALEC has been increased compared to 1 year ago.
Compared to 5 years ago, ALEC has more shares outstanding
The debt/assets ratio for ALEC is higher compared to a year ago.
ALEC Yearly Shares OutstandingALEC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALEC Yearly Total Debt VS Total AssetsALEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ALEC has an Altman-Z score of -2.86. This is a bad value and indicates that ALEC is not financially healthy and even has some risk of bankruptcy.
ALEC has a Altman-Z score (-2.86) which is in line with its industry peers.
ALEC has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALEC (0.10) is worse than 65.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -2.86
ROIC/WACCN/A
WACC9.58%
ALEC Yearly LT Debt VS Equity VS FCFALEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

ALEC has a Current Ratio of 3.34. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
ALEC's Current ratio of 3.34 is on the low side compared to the rest of the industry. ALEC is outperformed by 61.54% of its industry peers.
ALEC has a Quick Ratio of 3.34. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.34, ALEC is doing worse than 60.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.34
ALEC Yearly Current Assets VS Current LiabilitesALEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.70% over the past year.
Looking at the last year, ALEC shows a decrease in Revenue. The Revenue has decreased by -8.35% in the last year.
ALEC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.53% yearly.
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
Revenue 1Y (TTM)-8.35%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-76.88%

3.2 Future

Based on estimates for the next years, ALEC will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.94% on average per year.
The Revenue is expected to grow by 15.25% on average over the next years. This is quite good.
EPS Next Y-65.14%
EPS Next 2Y-16.5%
EPS Next 3Y6.81%
EPS Next 5Y9.94%
Revenue Next Year-83.59%
Revenue Next 2Y-10.11%
Revenue Next 3Y23.02%
Revenue Next 5Y15.25%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALEC Yearly Revenue VS EstimatesALEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ALEC Yearly EPS VS EstimatesALEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALEC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALEC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEC Price Earnings VS Forward Price EarningsALEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEC Per share dataALEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.5%
EPS Next 3Y6.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALEC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALECTOR INC

NASDAQ:ALEC (6/12/2025, 11:03:05 AM)

1.61

-0.02 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners87.59%
Inst Owner Change-0.91%
Ins Owners7.25%
Ins Owner Change-2.15%
Market Cap160.98M
Analysts77.33
Price Target5.18 (221.74%)
Short Float %5.96%
Short Ratio5.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.02%
Min EPS beat(2)17.12%
Max EPS beat(2)96.92%
EPS beat(4)4
Avg EPS beat(4)39.19%
Min EPS beat(4)17.12%
Max EPS beat(4)96.92%
EPS beat(8)8
Avg EPS beat(8)43.05%
EPS beat(12)10
Avg EPS beat(12)38.69%
EPS beat(16)11
Avg EPS beat(16)-1.92%
Revenue beat(2)1
Avg Revenue beat(2)101.11%
Min Revenue beat(2)-17.7%
Max Revenue beat(2)219.92%
Revenue beat(4)2
Avg Revenue beat(4)50.19%
Min Revenue beat(4)-17.7%
Max Revenue beat(4)219.92%
Revenue beat(8)5
Avg Revenue beat(8)156.01%
Revenue beat(12)7
Avg Revenue beat(12)117.15%
Revenue beat(16)7
Avg Revenue beat(16)76.8%
PT rev (1m)10.91%
PT rev (3m)5.17%
EPS NQ rev (1m)1.68%
EPS NQ rev (3m)-3.53%
EPS NY rev (1m)1.13%
EPS NY rev (3m)-10.43%
Revenue NQ rev (1m)-51.97%
Revenue NQ rev (3m)-77.35%
Revenue NY rev (1m)-3.68%
Revenue NY rev (3m)-74.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS0.88
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.23%
ROE -130.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.34
Altman-Z -2.86
F-Score1
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)45.58%
Cap/Depr(5y)54.45%
Cap/Sales(3y)2.26%
Cap/Sales(5y)6.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
EPS Next Y-65.14%
EPS Next 2Y-16.5%
EPS Next 3Y6.81%
EPS Next 5Y9.94%
Revenue 1Y (TTM)-8.35%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-76.88%
Revenue Next Year-83.59%
Revenue Next 2Y-10.11%
Revenue Next 3Y23.02%
Revenue Next 5Y15.25%
EBIT growth 1Y1.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.33%
EBIT Next 3Y12.79%
EBIT Next 5Y9.46%
FCF growth 1Y-10.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.48%
OCF growth 3YN/A
OCF growth 5YN/A